Differentiated Antiretroviral Therapy Distribution Models: Enablers and Barriers to Universal HIV Treatment in South Africa, Uganda, and Zimbabwe.
Anti-HIV Agents
/ supply & distribution
Anti-Retroviral Agents
/ supply & distribution
Antiretroviral Therapy, Highly Active
/ methods
Community Health Services
/ organization & administration
Female
Focus Groups
HIV Infections
/ drug therapy
Health Services Accessibility
Humans
Interviews as Topic
Male
Medication Adherence
/ psychology
Patient Care Team
Patient-Centered Care
Program Development
Qualitative Research
Social Capital
Social Stigma
South Africa
Uganda
Zimbabwe
Journal
The Journal of the Association of Nurses in AIDS Care : JANAC
ISSN: 1552-6917
Titre abrégé: J Assoc Nurses AIDS Care
Pays: United States
ID NLM: 9111870
Informations de publication
Date de publication:
Historique:
pubmed:
29
5
2019
medline:
17
9
2020
entrez:
29
5
2019
Statut:
ppublish
Résumé
Emerging HIV treatment distribution models across sub-Saharan Africa seek to overcome barriers to attaining antiretroviral therapy and to strengthen adherence in people living with HIV. We describe enablers, barriers, and benefits of differentiated treatment distribution models in South Africa, Uganda, and Zimbabwe. Data collection included semistructured interviews and focus group discussions with 163 stakeholders from policy, program, and patient levels. Four types of facility-based and 3 types of community-based models were identified. Enablers included policy, leadership, and guidance; functional information systems; strong care linkages; steady drug supply; patient education; and peer support. Barriers included insufficient drug supply, stigma, discrimination, and poor care linkages. Benefits included perceived improved adherence, peer support, reduced stigma and discrimination, increased time for providers to spend with complex patients, and travel and cost savings for patients. Differentiated treatment distribution models can enhance treatment access for patients who are clinically stable.
Identifiants
pubmed: 31135515
doi: 10.1097/JNC.0000000000000097
pmc: PMC6756295
doi:
Substances chimiques
Anti-HIV Agents
0
Anti-Retroviral Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e132-e143Références
Cochrane Database Syst Rev. 2013 Jun 27;(6):CD009987
pubmed: 23807693
Trop Med Int Health. 2010 Dec;15(12):1413-20
pubmed: 20958897
PLoS One. 2010 Sep 21;5(9):e12888
pubmed: 20877631
Trop Med Int Health. 2014 Aug;19(8):968-77
pubmed: 24889337
AIDS Res Treat. 2012;2012:574656
pubmed: 22461980
BMC Public Health. 2014 Apr 15;14:364
pubmed: 24735550
AIDS Care. 2018 Aug;30(8):1010-1016
pubmed: 29471667
J Int AIDS Soc. 2017 Jul 21;20(Suppl 4):21644
pubmed: 28770589
AIDS Res Treat. 2012;2012:749718
pubmed: 22577527
Trans R Soc Trop Med Hyg. 2009 Jun;103(6):594-600
pubmed: 19298993
Bull World Health Organ. 2008 Jul;86(7):559-67
pubmed: 18670668
BMC Health Serv Res. 2012 Jul 09;12:194
pubmed: 22776682
J Int AIDS Soc. 2016 Dec 01;19(1):21484
pubmed: 27914186
J Infect Dis. 2007 Dec 1;196 Suppl 3:S464-8
pubmed: 18181695
Ann Intern Med. 2011 Aug 16;155(4):209-16
pubmed: 21768555
J Int AIDS Soc. 2017 Jul 21;20(Suppl 4):21648
pubmed: 28770597
Psychol Health Med. 2015;20(4):488-94
pubmed: 25168720
BMC Health Serv Res. 2015 Nov 17;15:513
pubmed: 26577831
Int Health. 2013 Sep;5(3):169-79
pubmed: 24030268
J Int AIDS Soc. 2017 Jul 21;20(Suppl 4):21650
pubmed: 28770594